Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Viracta (Details)

v3.23.1
Royalty and Commercial Payment Purchase Agreements - Viracta (Details)
$ in Thousands
Mar. 22, 2021
USD ($)
item
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Agreements      
Long-term royalty and commercial payment receivables   $ 73,333 $ 63,683
Viracta | Royalty Purchase Agreement      
Agreements      
Number of drug candidates | item 2    
Payments related to purchase of royalty rights and other commercial payment rights $ 13,500    
Maximum amount of potential milestones and other payments receivable 54,000    
Amount of maximum consideration retained 20,000    
Maximum amount of potential regulatory and commercial milestones receivable 57,000    
Long-term royalty and commercial payment receivables $ 13,500    
Amount of allowance for credit losses   $ 0 $ 0